Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Life Science Investing
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Life Science Investing
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Life Science Investing
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting Life Science Investing
AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Life Science Investing
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update Life Science Investing
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment Life Science Investing
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting Life Science Investing
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium Life Science Investing
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson's Disease Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
